Harpoon Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>HT</div>
HARP -- USA Stock  

USD 17.26  0.84  5.12%

Harpoon Therapeutics Issuance Purchase of Equity Shares is very stable at the moment as compared to the past year. Harpoon Therapeutics reported last year Issuance Purchase of Equity Shares of 71.45 Million. As of 22nd of August 2020, Share Based Compensation is likely to grow to about 2.2 M, while Free Cash Flow is likely to drop (6.9 M). The next fiscal quarter end is expected on the 30th of September 2020. The stock is currently experiences an active upward rally. Many investors are getting excited about healthcare space, let's analyze if Harpoon Therapeutics fundamentals are strong enough to attract traders. We will analyze why it could be a much better year for Harpoon Therapeutics shareholders. We currently estimate Harpoon Therapeutics as undervalued. The real value is approaching 18.68 per share.
Published over three weeks ago
View all stories for Harpoon Therapeutics | View All Stories
Are Harpoon Therapeutics (NASDAQ:HARP) unfluctuating basic indicators contributing to the recent decline?
Our advice tool can cross-verify current analyst consensus on Harpoon Therapeutics and to analyze the company potential to grow in the current economic cycle. The firm dividends can provide a clue to the current value of the stock. The entity is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Harpoon Therapeutics income statement, its balance sheet, and the statement of cash flows. Potential Harpoon Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Harpoon Therapeutics investors may use each financial statement separately, they are all related. The changes in Harpoon Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Harpoon Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Harpoon Therapeutics fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Harpoon Therapeutics performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Harpoon Therapeutics shares is the value that is considered the true value of the share. If the intrinsic value Harpoon is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Harpoon Therapeutics. Please read more on our fundamental analysis page.

What is Harpoon Asset Breakdown?

Harpoon Therapeutics reports assets on its Balance Sheet. It represents the amount of Harpoon resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Harpoon volatility, please check the breakdown of all its fundamentals

Are Harpoon Therapeutics Earnings Expected to grow?

The future earnings power of Harpoon Therapeutics involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Harpoon Therapeutics factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Harpoon Therapeutics stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Harpoon expected earnings.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Harpoon Therapeutics, but it might be worth checking our own buy vs. sell analysis

Harpoon Therapeutics Gross Profit

Harpoon Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Harpoon Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Harpoon Therapeutics Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

A Deeper look at Harpoon

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Harpoon Therapeutics is not uncomon. Institutional investors typically avoid acquiring a high percentage of Harpoon Therapeutics stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Harpoon is distributed among investors.

Ownership Allocation

Harpoon Therapeutics has a total of twenty-five million one hundred fourty thousand outstanding shares. The majority of Harpoon Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Harpoon Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Harpoon Therapeutics. Please pay attention to any change in the institutional holdings of Harpoon Therapeutics as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Retail Investors
9.43%
Insiders
13.22%
Institutions
77.35%
Retail Investors9.43
Insiders13.22
Institutions77.35
 2010 2019 2020 (projected)
Interest Expense261 K327.75 K330.55 K
Gross Profit708 K5.78 M5.21 M

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Harpoon Therapeutics has an asset utilization ratio of 5.1 percent. This suggests that the company is making $0.051 for each dollar of assets. An increasing asset utilization means that Harpoon Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
119.6 M
Current Assets119.62 Million81.01
Assets Non Current28.04 Million18.99

Will Harpoon Therapeutics growth be real after the roll up?

Recent Information Ratio is up to -0.09. Price may decline again. Harpoon Therapeutics exhibits very low volatility with skewness of 0.78 and kurtosis of 3.43. However, we advise investors to further study Harpoon Therapeutics technical indicators to make sure all market info is available and is reliable.

Our Final Take On Harpoon Therapeutics

Although other companies in the biotechnology industry are either recovering or due for a correction, Harpoon may not be as strong as the others in terms of longer-term growth potentials. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor drop any shares of Harpoon Therapeutics at this time. The Harpoon Therapeutics risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Harpoon Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Harpoon Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com